Below are articles from various sources about members of MCB and their research.
Please visit the Sheikh Hamdan site for additional information about the award.
A pressure cooker with windows? That was the basic idea behind the bubble chamber, a powerful instrument for the study of atomic particles that led to a 1960 Nobel Prize in Physics for its inventor, UC Berkeley professor Donald Glaser.
UC Berkeley has been ranked as the second best University in the world in a survey by the Times Higher Education Supplement, a remarkable achievement for a public university.
The complete ranking are available at http://www.thes.co.uk/worldrankings/
Crammed inside every human cell are numerous strands of chromosomal DNA that, if laid end-to-end, would span a distance of about two meters. A special enzyme mechanically untangles the DNA, keeping our chromosomes from resembling a string of Christmas tree lights jammed into a box after the holiday. Someday, biochemist James Berger's efforts to understand the same enzyme in cancer cells could lead to new tumor-fighting drugs.
Assistant Professor Lu Chen has been awarded the prestigeous Packard Fellowship for Science and Engineering from the David and Lucile Packard Foundation.
For more information see:
Professor Hiroshi Nikaido will present this year's Roger Y. Stanier Memorial Lecture on Thursday November 4 in 100 Genetics & Plant Biology Building.
What happens when you touch a hot pan on the stove? You probably yell and yank your hand away. Between the sizzle and the scream though, an amazingly fast and complex cascade of cellular communication occurs inside your body.
To study the electrical intricacies of the nervous system, neurobiologist Ehud Isacoff is developing new optical methods that enable scientists to watch the cellular symphony unfold at the nanoscale.
The Department of Molecular and Cell Biology is seeking applications for four faculty positions.
Applications should include a curriculum vitae; a list of publications; a brief description of research accomplishments; a statement of research objectives and teaching interests; and reprints of three most significant publications. Please arrange to have three letters of reference sent to the address below. Applicants are expected to join the faculty July 1, 2005 or thereafter.
Four years ago, a new weapon in the war on cancer made it to clinical trials accompanied by headlines and hope. Gleevec, a drug manufactured by Novartis, appeared to selectively turn off a specific cancer-causing protein like a light switch, stopping the progress of a severe form of leukemia in its tracks.